Novocure (NVCR) – Business Wire
-
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meetin
-
Novocure to Report First Quarter 2024 Financial Results
-
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me
-
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C
-
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
-
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
-
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
-
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
-
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
-
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
-
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
-
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
-
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
-
Novocure Reports Third Quarter 2023 Financial Results
-
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
-
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
-
Novocure to Report Third Quarter 2023 Financial Results
-
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
-
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
-
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
-
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
-
Novocure to Participate in Upcoming Investor Conferences
-
Novocure Reports Second Quarter 2023 Financial Results
-
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
-
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
-
Novocure to Report Second Quarter 2023 Financial Results
-
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
-
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based
-
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
-
Novocure Reports First Quarter 2023 Financial Results
-
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
-
Novocure to Report First Quarter 2023 Financial Results
-
Kristin Stafford Joins Novocure Board of Directors
-
Virtual Incision Expands Leadership Team as it Prepares for New Market Growth
-
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
-
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
-
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
-
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
-
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
-
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
-
Novocure Announces Organizational Changes to Prepare for Future Growth
-
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
-
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
-
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
-
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
-
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
-
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
Back to NVCR Stock Lookup
